StructuralFunctional Study of AD - PowerPoint PPT Presentation

1 / 13
About This Presentation
Title:

StructuralFunctional Study of AD

Description:

Structural/Functional Study of AD. PI: Reisa Sperling. Multi-Site (Mass General and Brigham/Women's) ... Reisa Sperling R01 Proposal Feb 05. ADNI Ancillary ... – PowerPoint PPT presentation

Number of Views:27
Avg rating:3.0/5.0
Slides: 14
Provided by: reisasp
Category:

less

Transcript and Presenter's Notes

Title: StructuralFunctional Study of AD


1
Structural/Functional Study of AD
  • PI Reisa Sperling
  • Multi-Site (Mass General and Brigham/Womens)
  • Associative Memory Paradigm
  • Hippocampus, Inferior Frontal, Fusiform

2
fMRI Block Design Paradigm
  • Face-Name Pairs
  • Novel
  • Repeated

Contrast-of-Interest Novel-vs-Repeated
3
Preliminary Data
  • Thirteen AD subjects completed study with all
    three adequate fMRI scan sessions
  • Eight subjects on MGH Siemens 3T (Trio)
  • Five subjects on BWH GE 3T (long bore)
  • No cross-site data

4
Test-Retest Assessment
MGH
BWH
Percent N-v-R Contrast
Test
Retest
5
T2 Mapping
  • Same Agar Phantom
  • EPI Sequences TE 30, 35, 40, 45 ms
  • Average T2
  • 42.03 ms (GE)
  • 42.22 ms (Siemens)

6
Reisa Sperling R01 Proposal Feb 05
  • ADNI Ancillary Studies PA
  • Reproducibility of fMRI
  • Face-name associative memory
  • Relationship of fMRI to clinical variablilites
  • Two sites, BWH, MGH
  • Study structure parallels main ADNI study
  • Preparatory
  • Longitudinal

7
  • Aim 1 quantify cross-scanner reproducibility and
    test-retest stability..
  • Compare extent and magnitude of activation within
    each ROI across scanners
  • ICC reproducibility analyses (Zou in press)
  • Compare within subject and between subject
    variance

8
(No Transcript)
9
(No Transcript)
10
fMRI AMPA Potentiator Study Design
LY451395 (0.2 mg BID) or Placebo
LY451395 (1.0 mg BID) or Placebo
Baseline
ScreeningVisit
Scan 3
Scan 1
Scan 2
-7 to -9days
Week 9
Week 0
Week 5
11
(No Transcript)
12
fMRI Block Design Test-Retest Reliability in AD
patient
13
Differences in prefrontal activation in LY451395
vs. placebo
Session 3 gt Session 1 for Drug (n4) gt
Placebo (n9)
Write a Comment
User Comments (0)
About PowerShow.com